About this trial

More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.

Eligibility criteria

Qualifiers

All individuals attending the preventive cardiology clinics.

Disqualifiers

• Individuals who refused to give consent.

Trial design

Treatments tested in this trial

  • Cardiovascular risk assesment

Treatment groups

10,000 Participants
are divided into 1 treatment group

Locations

1
National Institute of Cardiovascular Diseases75510, KarachiSindh, Pakistan

Sponsors and collaborators

National Institute of Cardiovascular Diseases, Pakistan

Lead sponsor